E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or
 Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD)
 patients with secondary hyperparathyroidism (HPT) who are receiving dialysis.
Secondary HPT is common in people with CKD. Patients with secondary HPT often have high
 parathyroid hormone (PTH) levels and may develop large parathyroid glands in the neck.
 Patients with secondary HPT may have bone disease (osteodystrophy). This bone disease may
 cause bone pain, fractures, and poor formation of red blood cells. Other problems from
 secondary HPT may include increases in blood levels of calcium and phosphorus. These may
 cause calcium to deposit in body tissues. Calcium deposits can cause arthritis (joint pain
 and swelling), muscle inflammation, itching, gangrene (death of soft tissue), or heart and
 lung problems. New evidence suggests that secondary HPT is associated with cardiovascular
 disease and increased death risk. The purpose of this study is to evaluate the effects of
 cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events (having to do with
 the heart and its blood vessels) and death in chronic kidney disease (CKD) patients with
 secondary hyperparathyroidism (HPT) who are receiving dialysis. These events include death
 from any reason, heart attack and episodes where the heart does not get enough oxygen,
 peripheral vascular disease (narrowing of vessels that carry blood to the legs, arms, stomach
 or kidneys), and heart failure (a condition that occurs when the heart is unable to pump
 enough blood to meet the need's of the body's tissues)
Inclusion Criteria:

 -  Inclusion:≥ 18 years of age

 -  Treated with maintenance hemodialysis - PTH ≥ 300 pg/mL (31.8 pmol/L)

 -  serum calcium ≥ 8.4mg/dL (2.1 mmol/L)

 -  Ca x P ≥ 45 mg2*/dL2 (3.63 mmol2/L2)

 Exclusion Criteria: - Exclusion:

 -  Parathyroidectomy in the 12 weeks before the date of informed consent

 -  Received therapy with cinacalcet within 3 months of randomization

 -  Hospitalization within 12 weeks of randomization for any of the following events: a.
 Myocardial ischemia b. Unstable angina c. Heart Failure (HF) (including any unplanned
 presentation to a health care facility that would require mechanical intervention
 [i.e., unplanned dialysis treatment]) d. Peripheral vascular disease (other than
 dialysis vascular access revision) e. Stroke

 -  History of seizure within 12 weeks prior to randomization

 -  Scheduled date for kidney transplant from a known living donor

 -  Anticipated parathyroidectomy within 6 months after randomization

 -  in all instances, the 2 refers to squared.